<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01220466</url>
  </required_header>
  <id_info>
    <org_study_id>STAR-108-IDSN</org_study_id>
    <nct_id>NCT01220466</nct_id>
  </id_info>
  <brief_title>Performance and Acceptability of iDesign</brief_title>
  <official_title>A Prospective Study to Evaluate the Performance and Acceptability of the iDesign Advanced WaveScan Study(tm) System</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abbott Medical Optics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abbott Medical Optics</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The results of this trial will demonstrate that the iDesign System performs as intended and
      is acceptable in a clinical setting.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      LASIK treatment across the range of myopia with or without astigmatism, hyperopia with or
      without astigmatism, and mixed astigmatism.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2010</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <primary_completion_date type="Actual">June 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Eyes With Uncorrected Visual Acuity (UCVA) of 20/40 or Better.</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <other_outcome>
    <measure>Percentage of Eyes With Manifest Refraction Spherical Equivalent Within 1.0 D</measure>
    <time_frame>6 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Percentage of Eyes With Loss of More Than 2 Lines Best Spectacle Corrected Visual Acuity (BSCVA)</measure>
    <time_frame>6 Months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Percentage of Eyes With Best Spectacle Corrected Visual Acuity (BSCVA) Worse Than 20/40</measure>
    <time_frame>6 Months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Percentage of Eyes With Induced Manifest Refractive Astigmatism Greater Than 2.00 D of Absolute Cylinder as Compared to the Preoperative Refraction</measure>
    <time_frame>6 Months</time_frame>
    <description>Induced Manifest Refractive Astigmatism is an increase of astigmatism (cylinder) postoperatively that could be caused by the refractive treatment. An increase of greater than 2.0 D is considered a safety endpoint per ANSI Z80.11-2007.</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">77</enrollment>
  <condition>Refractive Error</condition>
  <arm_group>
    <arm_group_label>Refractive Error</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>STAR S4IR LASIK with iDesign Aberrometer</intervention_name>
    <description>CustomVue LASIK targeted for emmetropia</description>
    <arm_group_label>Refractive Error</arm_group_label>
    <other_name>CustomVue</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female, of any race, and at least 18 years old at the time the consent form is
             signed.

          -  The refractive error, based on manifest refraction (adjusted for optical infinity),
             must be MRSE up to -15.00 D with manifest cylinder between 0.00 and -6.00 D; MRSE up
             to +9.00 D with cylinder between 0.00 and +6.00 D; or manifest cylinder (from 1.00 to
             6.00 D) greater than the magnitude of sphere, and the cylinder and sphere have
             opposite signs.

          -  BSCVA of 20/20 or better.

          -  UCVA:

               -  Myopes must be 20/40 or worse.

               -  Subjects with Hyperopia or mixed astigmatism, treatment may be based on
                  difficulty maintaining UCVA of 20/40 evidenced by spectacle/contact lens
                  dependence for distance, as documented by the investigator.

          -  Wavefront diameter ≥ 4.0 mm.

          -  Sufficient agreement between manifest refraction (adjusted for optical infinity) and
             iDesign System refraction (sphere, cylinder, and axis) to allow treatment selection
             and generation of an ablation profile as determined by the investigational iDesign
             System software.

          -  Manifest refraction sphere within ± 0.75 D of cycloplegic refraction sphere.

          -  Anticipated post-operative stromal bed thickness of at least 250 microns, based on
             pre-operative central corneal pachymetry minus the maximum treatment depth to be
             ablated (as calculated by the iDesign System) and the intended flap thickness.

          -  Anticipated post-operative keratometry value (based on pre-operative iDesign System
             refraction and keratometry) that is appropriate.

          -  A stable refractive error (based on a previous exam, medical records, or prescription)
             as compared to the unadjusted pre-operative manifest refraction.

          -  Subjects who currently wear contact lenses must demonstrate refractive stability in
             the operative eye. Rigid or toric lenses must be removed for at least 2 weeks and SCL
             for at least 3 days prior to the first refraction used to establish stability. A
             second refraction with a change of no more than ± 0.50 D MRSE at least 7 days after
             baseline.

          -  Willing and capable of returning for follow-up examinations for the duration of the
             study.

        Exclusion Criteria:

          -  Women who are pregnant, breast-feeding, or intend to become pregnant over the course
             of the study, as determined by verbal inquiry, or another condition associated with
             the fluctuation of hormones that could lead to refractive changes.

          -  Subjects with an ametropic or amblyopic fellow eye not meeting all inclusion criteria
             that does not fall within the indications for treatment using the VISX® STAR S4 IR™
             Excimer Laser.

          -  Concurrent use of systemic (including inhaled) medications that may impair healing,
             including but not limited to: steroids, antimetabolites, isotretinoin (Accutane™)
             within 6 months of treatment, and amiodarone hydrochloride (Cordarone™) within 12
             months of treatment.

          -  Acute or chronic disease, illness, or treatment that would increase the operative risk
             (e.g., immuno-compromised, autoimmune disease, connective tissue disease, clinically
             significant atopic disease, diabetes, etc.).

          -  Subjects with a cardiac pacemaker, implanted defibrillator, implanted neurostimulator,
             or any active electrical implants.

          -  Ocular condition (other than high myopia) that may predispose the subject to future
             complications, such as history or evidence of active or inactive corneal disease

          -  Previous intraocular or corneal surgery that might confound the outcome of the study
             or increase risk to the subject.

          -  Known sensitivity or inappropriate responsiveness to any of the medications used in
             the post-operative course.

          -  Concurrent participation in any other clinical study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nicholas Tarantino, OD</last_name>
    <role>Study Director</role>
    <affiliation>Abbott Medical Optics</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clearly LASIK</name>
      <address>
        <city>Victoria</city>
        <state>British Columbia</state>
        <zip>V8X 1X2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Image Plus Laser Eye Center</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R3C 3J5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Ottawa Eye Institute, The Ottawa Hospital</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 8L6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yonge-Eglington Laser</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4P 2E5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>May 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 24, 2010</study_first_submitted>
  <study_first_submitted_qc>October 12, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 14, 2010</study_first_posted>
  <results_first_submitted>February 15, 2013</results_first_submitted>
  <results_first_submitted_qc>May 16, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 20, 2013</results_first_posted>
  <last_update_submitted>May 16, 2013</last_update_submitted>
  <last_update_submitted_qc>May 16, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 20, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Refractive Errors</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>One or both eyes of 77 subjects (143 eyes) were treated. This includes a predominance of Caucasian participants and a mean age of 37.2 years.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Hyperopia With or Without Astigmatism</title>
          <description>Hyperopia with and without astigmatism with MRSE up to
+9.00 D, with cylinder between 0.00 and +6.00 D.</description>
        </group>
        <group group_id="P2">
          <title>Myopia With or Without Astigmatism</title>
          <description>Myopia with and without astigmatism with MRSE up to -15.0D, with cylinder between 0.00 and -6.00 D.</description>
        </group>
        <group group_id="P3">
          <title>Mixed Astigmatism</title>
          <description>Mixed Astigmatism when the magnitude of cylinder (from 1.0 to 6.0D ) is greater than the magnitude of sphere, and the cylinder and sphere have opposite signs.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="11">19 eyes</participants>
                <participants group_id="P2" count="56">108 eyes</participants>
                <participants group_id="P3" count="10">16 eyes</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11">19 eyes</participants>
                <participants group_id="P2" count="56">108 eyes</participants>
                <participants group_id="P3" count="10">16 eyes</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Hyperopia With or Without Astigmatism</title>
          <description>Hyperopia with and without astigmatism with MRSE up to
+9.00 D, with cylinder between 0.00 and +6.00 D.</description>
        </group>
        <group group_id="B2">
          <title>Myopia With or Without Astigmatism</title>
          <description>Myopia with and without astigmatism with MRSE up to -15.0D, with cylinder between 0.00 and -6.00 D.</description>
        </group>
        <group group_id="B3">
          <title>Mixed Astigmatism</title>
          <description>Mixed Astigmatism when the magnitude of cylinder (from 1.0 to 6.0D ) is greater than the magnitude of sphere, and the cylinder and sphere have opposite signs.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="11"/>
            <count group_id="B2" value="56"/>
            <count group_id="B3" value="10"/>
            <count group_id="B4" value="77"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="56"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="56"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Eyes With Uncorrected Visual Acuity (UCVA) of 20/40 or Better.</title>
        <time_frame>6 months</time_frame>
        <population>UCVA is reported as percentage of eyes not percentage of subjects achieving UCVA of 20/40 or better</population>
        <group_list>
          <group group_id="O1">
            <title>Myopia With and Without Astigmatism</title>
            <description>Myopia with and without astigmatism with MRSE up to -15.0 D, with cylinder between 0.00 and -6.00 D.</description>
          </group>
          <group group_id="O2">
            <title>Hyperopia With and Without Astigmatism</title>
            <description>Hyperopia with and without astigmatism with MRSE up to +9.00 D, with cylinder between 0.00 and +6.00 D</description>
          </group>
          <group group_id="O3">
            <title>Mixed Astigmatism</title>
            <description>Mixed Astigmatism when the magnitude of cylinder (from 1.0 to 6.0D) is greater than the magnitude of sphere, and the cylinder and sphere have opposite signs.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Eyes With Uncorrected Visual Acuity (UCVA) of 20/40 or Better.</title>
          <population>UCVA is reported as percentage of eyes not percentage of subjects achieving UCVA of 20/40 or better</population>
          <units>percentage of eyes</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="10"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="108"/>
                <count group_id="O2" value="19"/>
                <count group_id="O3" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="97.3" upper_limit="100"/>
                    <measurement group_id="O2" value="100" lower_limit="85.4" upper_limit="100"/>
                    <measurement group_id="O3" value="100" lower_limit="82.9" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Percentage of Eyes With Manifest Refraction Spherical Equivalent Within 1.0 D</title>
        <time_frame>6 months</time_frame>
        <population>Percent of eyes that achieved manifest refraction spherical equivalent within 1.0 D</population>
        <group_list>
          <group group_id="O1">
            <title>Myopia With and Without Astigmatism</title>
            <description>Myopia with and without astigmatism with MRSE up to -15.0 D, with cylinder between 0.00 and -6.00 D.</description>
          </group>
          <group group_id="O2">
            <title>Hyperopia With and Without Astigmatism</title>
            <description>Hyperopia with and without astigmatism with MRSE up to +9.00 D, with cylinder between 0.00 and +6.00 D</description>
          </group>
          <group group_id="O3">
            <title>Mixed Astigmatism</title>
            <description>Mixed Astigmatism when the magnitude of cylinder (from 1.0 to 6.0D) is greater than the magnitude of sphere, and the cylinder and sphere have opposite signs.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Eyes With Manifest Refraction Spherical Equivalent Within 1.0 D</title>
          <population>Percent of eyes that achieved manifest refraction spherical equivalent within 1.0 D</population>
          <units>percentage of eyes</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="10"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="108"/>
                <count group_id="O2" value="19"/>
                <count group_id="O3" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.1" lower_limit="94.9" upper_limit="100"/>
                    <measurement group_id="O2" value="89.5" lower_limit="66.9" upper_limit="98.7"/>
                    <measurement group_id="O3" value="93.8" lower_limit="69.8" upper_limit="99.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Percentage of Eyes With Loss of More Than 2 Lines Best Spectacle Corrected Visual Acuity (BSCVA)</title>
        <time_frame>6 Months</time_frame>
        <population>Percent of eyes that lost more than 2 lines of BSCVA.</population>
        <group_list>
          <group group_id="O1">
            <title>Myopia With and Without Astigmatism</title>
            <description>Myopia with and without astigmatism with MRSE up to -15.0 D, with cylinder between 0.00 and -6.00 D.</description>
          </group>
          <group group_id="O2">
            <title>Hyperopia With and Without Astigmatism</title>
            <description>Hyperopia with and without astigmatism with MRSE up to +9.00 D, with cylinder between 0.00 and +6.00 D</description>
          </group>
          <group group_id="O3">
            <title>Mixed Astigmatism</title>
            <description>Mixed Astigmatism when the magnitude of cylinder (from 1.0 to 6.0D) is greater than the magnitude of sphere, and the cylinder and sphere have opposite signs.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Eyes With Loss of More Than 2 Lines Best Spectacle Corrected Visual Acuity (BSCVA)</title>
          <population>Percent of eyes that lost more than 2 lines of BSCVA.</population>
          <units>percentage of eyes</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="10"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="108"/>
                <count group_id="O2" value="19"/>
                <count group_id="O3" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0">Confidence intervals were not calculated because 0% of eyes lost more than 2 lines of BSCVA.</measurement>
                    <measurement group_id="O2" value="5.3" lower_limit="0.1" upper_limit="26"/>
                    <measurement group_id="O3" value="0">Confidence intervals were not calculated because 0% of eyes lost more than 2 lines of BSCVA.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Percentage of Eyes With Best Spectacle Corrected Visual Acuity (BSCVA) Worse Than 20/40</title>
        <time_frame>6 Months</time_frame>
        <population>Percentage of eyes with BSCVA worse than 20/40</population>
        <group_list>
          <group group_id="O1">
            <title>Myopia With and Without Astigmatism</title>
            <description>Myopia with and without astigmatism with MRSE up to -15.0 D, with cylinder between 0.00 and -6.00 D.</description>
          </group>
          <group group_id="O2">
            <title>Hyperopia With and Without Astigmatism</title>
            <description>Hyperopia with and without astigmatism with MRSE up to +9.00 D, with cylinder between 0.00 and +6.00 D</description>
          </group>
          <group group_id="O3">
            <title>Mixed Astigmatism</title>
            <description>Mixed Astigmatism when the magnitude of cylinder (from 1.0 to 6.0D) is greater than the magnitude of sphere, and the cylinder and sphere have opposite signs.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Eyes With Best Spectacle Corrected Visual Acuity (BSCVA) Worse Than 20/40</title>
          <population>Percentage of eyes with BSCVA worse than 20/40</population>
          <units>percentage of eyes</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="10"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="108"/>
                <count group_id="O2" value="19"/>
                <count group_id="O3" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0">Confidence intervals were not calculated because 0% of eyes had BSCVA worse than 20/40.</measurement>
                    <measurement group_id="O2" value="0">Confidence intervals were not calculated because 0% of eyes had BSCVA worse than 20/40.</measurement>
                    <measurement group_id="O3" value="0">Confidence intervals were not calculated because 0% of eyes had BSCVA worse than 20/40.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Percentage of Eyes With Induced Manifest Refractive Astigmatism Greater Than 2.00 D of Absolute Cylinder as Compared to the Preoperative Refraction</title>
        <description>Induced Manifest Refractive Astigmatism is an increase of astigmatism (cylinder) postoperatively that could be caused by the refractive treatment. An increase of greater than 2.0 D is considered a safety endpoint per ANSI Z80.11-2007.</description>
        <time_frame>6 Months</time_frame>
        <population>Percentage of eyes with induced manifest refractive astigmatism greater than 2.00 D of absolute cylinder power</population>
        <group_list>
          <group group_id="O1">
            <title>Myopia With and Without Astigmatism</title>
            <description>Myopia with and without astigmatism with MRSE up to -15.0 D, with cylinder between 0.00 and -6.00 D.</description>
          </group>
          <group group_id="O2">
            <title>Hyperopia With and Without Astigmatism</title>
            <description>Hyperopia with and without astigmatism with MRSE up to +9.00 D, with cylinder between 0.00 and +6.00 D</description>
          </group>
          <group group_id="O3">
            <title>Mixed Astigmatism</title>
            <description>Mixed Astigmatism when the magnitude of cylinder (from 1.0 to 6.0D) is greater than the magnitude of sphere, and the cylinder and sphere have opposite signs.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Eyes With Induced Manifest Refractive Astigmatism Greater Than 2.00 D of Absolute Cylinder as Compared to the Preoperative Refraction</title>
          <description>Induced Manifest Refractive Astigmatism is an increase of astigmatism (cylinder) postoperatively that could be caused by the refractive treatment. An increase of greater than 2.0 D is considered a safety endpoint per ANSI Z80.11-2007.</description>
          <population>Percentage of eyes with induced manifest refractive astigmatism greater than 2.00 D of absolute cylinder power</population>
          <units>percentage of eyes</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <units_analyzed>Participants</units_analyzed>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="56"/>
                <count group_id="O2" value="11"/>
                <count group_id="O3" value="10"/>
              </count_list>
            </analyzed>
            <analyzed>
              <units>eyes</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="108"/>
                <count group_id="O2" value="19"/>
                <count group_id="O3" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0">Confidence intervals were not calculated because 0% of eyes had induced manifest refractive astigmatism greater than 2.00 D of absolute cylinder power.</measurement>
                    <measurement group_id="O2" value="0">Confidence intervals were not calculated because 0% of eyes had induced manifest refractive astigmatism greater than 2.00 D of absolute cylinder power.</measurement>
                    <measurement group_id="O3" value="0">Confidence intervals were not calculated because 0% of eyes had induced manifest refractive astigmatism greater than 2.00 D of absolute cylinder power.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Hyperopia With and Without Astigmatism</title>
          <description>Hyperopia with and without astigmatism with MRSE up to +9.00 D, with cylinder between 0.00 and +6.00 D</description>
        </group>
        <group group_id="E2">
          <title>Myopia With and Without Astigmatism</title>
          <description>Myopia with and without astigmatism with MRSE up to -15.0 D, with cylinder between 0.00 and -6.00 D.</description>
        </group>
        <group group_id="E3">
          <title>Mixed Astigmatism</title>
          <description>Mixed Astigmatism when the magnitude of cylinder (from 1.0 to 6.0D) is greater than the magnitude of sphere, and the cylinder and sphere have opposite signs.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="56"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Decrease in BSCVA of greater than or equal to two lines</sub_title>
                <description>Loss of greater than two lines of BSCVA is a SAE in the context of this study. Decrease in BSCVA of greater than or equal to 2 lines (10 letters) not due to irregular astigmatism as shown by hard contact lens refraction, at 3 months or later.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="56"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="56"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Corneal epithelial defect</sub_title>
                <assessment>Non-systematic Assessment</assessment>
                <description>Corneal epithelial defect of any kind, involving the keratometry at 1 month or later</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Foreign body in the eye</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Miscreated flap</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>retinal tear/hole</sub_title>
                <description>One subject in the myopia cohort had a retinal tear/hole in both the right and left eye.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Other - car accident</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="11"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="56"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
              <event>
                <sub_title>Other - concussion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="56"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="10"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Amelia Saliba, Sr. Manager, Clinical Research</name_or_title>
      <organization>Abbott Medical Optics</organization>
      <phone>408-273-4158</phone>
      <email>amelia.saliba@amo.abbott.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

